Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 2/20 | 0.54 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.54 |
| ▸ | SPR | P35270 | 1/20 | 0.50 |
| ▸ | KDM5A | P29375 | 2/20 | 0.48 |
| ▸ | SCD5 | Q86SK9 | 5/20 | 0.48 |
| ▸ | NAMPT | P43490 | 1/20 | 0.47 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.47 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.47 |
| ▸ | MAP3K12 | Q12852 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.40 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.40 |
| ▸ | WDR77 | Q9BQA1 | 2/20 | 0.40 |
| ▸ | GRM5 | P41594 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3551014 | 0.92 | NAMPT (0.58) | HCRTR1HCRTR2SPRKDM5ASCD5 | |
| SCHEMBL3549063 | 0.92 | HSD11B1 (0.56) | HCRTR1HCRTR2SPRKDM5ASCD5 | |
| SCHEMBL3552843 | 0.92 | HCRTR1 (0.51) | HCRTR1HCRTR2SPRKDM5ASCD5 | |
| SCHEMBL3549187 | 0.92 | SPR (0.47) | HCRTR1HCRTR2SPRKDM5ASCD5 | |
| SCHEMBL3546542 | 0.89 | SPR (0.54) | HCRTR1HCRTR2SPRKDM5ASCD5 | |
| SCHEMBL3546304 | 0.86 | SPR (0.54) | HCRTR1HCRTR2SPRKDM5ASCD5 | |
| SCHEMBL3542458 | 0.85 | SCD5 (0.60) | HCRTR1HCRTR2SCD5TP53 | |
| SCHEMBL3547361 | 0.84 | HCRTR1 (0.55) | HCRTR1HCRTR2SPRSCD5 | |
| SCHEMBL3551569 | 0.82 | HCRTR1 (0.53) | HCRTR1HCRTR2SPRSCD5NAMPT | |
| SCHEMBL13501692 | 0.82 | HCRTR1 (0.53) | HCRTR1HCRTR2SPRSCD5NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7666888-B2 | Substituted azole aromatic heterocycles as inhibitors of 11β-HSD-1 | AMGEN INC. (US) | 2010-02-23 | — | — | US | disclosed |
| US-7666888-B2 | Substituted azole aromatic heterocycles as inhibitors of 11β-HSD-1 | AMGEN INC. (US) | 2010-02-23 | — | — | US | disclosed |
| US-7666888-B2 | Substituted azole aromatic heterocycles as inhibitors of 11β-HSD-1 | AMGEN INC. (US) | 2010-02-23 | — | — | US | disclosed |
| WO-2008011453-A2 | SUBSTITUTED AZOLE AROMATIC HETEROCYCLES AS INHIBITORS OF LLβ-HSD-1 | AMGEN INC. (US) | 2008-01-24 | — | — | WO | disclosed |
| US-20080021022-A1 | SUBSTITUTED AZOLE AROMATIC HETEROCYCLES AS INHIBITORS OF 11BETA-HSD-1 | AMGEN INC. | 2008-01-24 | — | — | US | disclosed |
| US-20080021022-A1 | SUBSTITUTED AZOLE AROMATIC HETEROCYCLES AS INHIBITORS OF 11BETA-HSD-1 | AMGEN INC. | 2008-01-24 | — | — | US | disclosed |
| US-20080021022-A1 | SUBSTITUTED AZOLE AROMATIC HETEROCYCLES AS INHIBITORS OF 11BETA-HSD-1 | AMGEN INC. | 2008-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080021022-A1 | SUBSTITUTED AZOLE AROMATIC HETEROCYCLES AS INHIBITORS OF 11BETA-HSD-1 | HSD17B1, HSD11B1, HSD17B11 | HCRTR1 314/4885HCRTR2 531/4885SPR 256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.